CA2708021A1 - Procede permettant de detecter des effecteurs de l'activite protease de cis/trans isomerases - Google Patents

Procede permettant de detecter des effecteurs de l'activite protease de cis/trans isomerases Download PDF

Info

Publication number: CA2708021A1
Authority: CA; Canada
Prior art keywords: cis; trans isomerase; trans; molecule; proenzyme
Prior art date: 2007-12-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2708021A

Other languages

English (en)

Inventor

Gunter Fischer

Cordelia Schiene-Fischer

Tobias Aumueller

Guenther Jahreis

Gerhard Kuellertz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Max Planck Gesellschaft zur Foerderung der Wissenschaften

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-04

Filing date

2008-12-04

Publication date

2009-06-11

2008-12-04 Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften

2009-06-11 Publication of CA2708021A1 publication Critical patent/CA2708021A1/fr

Status Abandoned legal-status Critical Current

Links

102000004195 Isomerases Human genes 0.000 title claims abstract description 240
108090000769 Isomerases Proteins 0.000 title claims abstract description 240
238000000034 method Methods 0.000 title claims abstract description 132
239000012636 effector Substances 0.000 title claims abstract description 50
230000000694 effects Effects 0.000 title claims description 112
108091005804 Peptidases Proteins 0.000 title claims description 67
239000004365 Protease Substances 0.000 title claims description 67
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims description 63
230000002401 inhibitory effect Effects 0.000 claims abstract description 16
230000003213 activating effect Effects 0.000 claims abstract description 12
239000000758 substrate Substances 0.000 claims description 102
108010062466 Enzyme Precursors Proteins 0.000 claims description 82
102000010911 Enzyme Precursors Human genes 0.000 claims description 82
239000000126 substance Substances 0.000 claims description 38
102000004190 Enzymes Human genes 0.000 claims description 30
108090000790 Enzymes Proteins 0.000 claims description 30
239000003112 inhibitor Substances 0.000 claims description 28
238000001514 detection method Methods 0.000 claims description 25
108090000623 proteins and genes Proteins 0.000 claims description 23
102000004169 proteins and genes Human genes 0.000 claims description 22
108090000765 processed proteins & peptides Proteins 0.000 claims description 20
102000001493 Cyclophilins Human genes 0.000 claims description 19
108010068682 Cyclophilins Proteins 0.000 claims description 19
230000027455 binding Effects 0.000 claims description 17
108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 12
102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 12
230000006337 proteolytic cleavage Effects 0.000 claims description 9
239000000463 material Substances 0.000 claims description 6
239000012190 activator Substances 0.000 claims description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
108090001008 Avidin Proteins 0.000 claims description 2
108010090804 Streptavidin Proteins 0.000 claims description 2
229960002685 biotin Drugs 0.000 claims description 2
235000020958 biotin Nutrition 0.000 claims description 2
239000011616 biotin Substances 0.000 claims description 2
239000012456 homogeneous solution Substances 0.000 claims description 2
238000002796 luminescence method Methods 0.000 claims description 2
238000001179 sorption measurement Methods 0.000 claims description 2
238000004611 spectroscopical analysis Methods 0.000 claims description 2
238000002848 electrochemical method Methods 0.000 claims 1
238000006243 chemical reaction Methods 0.000 description 79
239000000243 solution Substances 0.000 description 35
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 32
229930105110 Cyclosporin A Natural products 0.000 description 32
108010036949 Cyclosporine Proteins 0.000 description 32
229960001265 ciclosporin Drugs 0.000 description 32
230000005764 inhibitory process Effects 0.000 description 25
238000005259 measurement Methods 0.000 description 24
239000000047 product Substances 0.000 description 23
230000003993 interaction Effects 0.000 description 22
238000011534 incubation Methods 0.000 description 20
235000018102 proteins Nutrition 0.000 description 19
102100037026 Peptidyl-prolyl cis-trans isomerase FKBP5 Human genes 0.000 description 18
239000000203 mixture Substances 0.000 description 17
108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 16
239000003814 drug Substances 0.000 description 14
238000011160 research Methods 0.000 description 13
238000006555 catalytic reaction Methods 0.000 description 12
238000006317 isomerization reaction Methods 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
238000003776 cleavage reaction Methods 0.000 description 11
229960001760 dimethyl sulfoxide Drugs 0.000 description 11
230000007062 hydrolysis Effects 0.000 description 11
238000006460 hydrolysis reaction Methods 0.000 description 11
230000002797 proteolythic effect Effects 0.000 description 11
230000007017 scission Effects 0.000 description 11
102000004631 Calcineurin Human genes 0.000 description 10
108010042955 Calcineurin Proteins 0.000 description 10
150000001408 amides Chemical class 0.000 description 10
238000003556 assay Methods 0.000 description 10
230000008901 benefit Effects 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
239000007995 HEPES buffer Substances 0.000 description 9
230000004913 activation Effects 0.000 description 9
238000001994 activation Methods 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
238000004891 communication Methods 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
238000010327 methods by industry Methods 0.000 description 8
238000012360 testing method Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
239000000872 buffer Substances 0.000 description 7
230000008859 change Effects 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
102000015636 Oligopeptides Human genes 0.000 description 6
108010038807 Oligopeptides Proteins 0.000 description 6
102220467287 Peptidyl-prolyl cis-trans isomerase-like 1_R55A_mutation Human genes 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
239000007850 fluorescent dye Substances 0.000 description 6
230000001506 immunosuppresive effect Effects 0.000 description 6
KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 description 6
UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 5
101710111214 Peptidyl-prolyl cis-trans isomerase C Proteins 0.000 description 5
102100031653 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 Human genes 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000007795 chemical reaction product Substances 0.000 description 5
239000000470 constituent Substances 0.000 description 5
230000017854 proteolysis Effects 0.000 description 5
230000035484 reaction time Effects 0.000 description 5
241000196324 Embryophyta Species 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
238000013375 chromatographic separation Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
238000006911 enzymatic reaction Methods 0.000 description 4
230000002349 favourable effect Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
WNDDWSAHNYBXKY-UHFFFAOYSA-N ATTO 425-2 Chemical compound CC1CC(C)(C)N(CCCC(O)=O)C2=C1C=C1C=C(C(=O)OCC)C(=O)OC1=C2 WNDDWSAHNYBXKY-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
101000741800 Homo sapiens Peptidyl-prolyl cis-trans isomerase H Proteins 0.000 description 3
102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 3
102100038827 Peptidyl-prolyl cis-trans isomerase H Human genes 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
239000000134 cyclophilin inhibitor Substances 0.000 description 3
230000000093 cytochemical effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
239000003394 isomerase inhibitor Substances 0.000 description 3
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
230000037230 mobility Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000011002 quantification Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
108010067247 tacrolimus binding protein 4 Proteins 0.000 description 3
GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 2
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
102000004482 ATP Translocases Mitochondrial ADP Human genes 0.000 description 2
108010017236 ATP Translocases Mitochondrial ADP Proteins 0.000 description 2
206010001497 Agitation Diseases 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
101000932178 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 description 2
101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 2
101000878221 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 description 2
102000000521 Immunophilins Human genes 0.000 description 2
108010016648 Immunophilins Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
229940118465 Isomerase inhibitor Drugs 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
108010047320 Pepsinogen A Proteins 0.000 description 2
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
102100036978 Peptidyl-prolyl cis-trans isomerase FKBP8 Human genes 0.000 description 2
102100034850 Peptidyl-prolyl cis-trans isomerase G Human genes 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
229960004050 aminobenzoic acid Drugs 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 description 2
238000002306 biochemical method Methods 0.000 description 2
238000005842 biochemical reaction Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002189 fluorescence spectrum Methods 0.000 description 2
238000013537 high throughput screening Methods 0.000 description 2
230000000937 inactivator Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
238000012933 kinetic analysis Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000005445 natural material Substances 0.000 description 2
239000002547 new drug Substances 0.000 description 2
244000045947 parasite Species 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000012216 screening Methods 0.000 description 2
150000003334 secondary amides Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
108010037365 Arabidopsis Proteins Proteins 0.000 description 1
101100007506 Arabidopsis thaliana CYP20-1 gene Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
102100029968 Calreticulin Human genes 0.000 description 1
108090000549 Calreticulin Proteins 0.000 description 1
102000052052 Casein Kinase II Human genes 0.000 description 1
108010010919 Casein Kinase II Proteins 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
108010038061 Chymotrypsinogen Proteins 0.000 description 1
YPHMISFOHDHNIV-FSZOTQKASA-N Cycloheximide Natural products C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
208000001490 Dengue Diseases 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000244160 Echinococcus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
102000018389 Exopeptidases Human genes 0.000 description 1
108010091443 Exopeptidases Proteins 0.000 description 1
102100025894 Glomulin Human genes 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
206010019842 Hepatomegaly Diseases 0.000 description 1
101000857303 Homo sapiens Glomulin Proteins 0.000 description 1
101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
240000007049 Juglans regia Species 0.000 description 1
235000009496 Juglans regia Nutrition 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
241000222732 Leishmania major Species 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000005431 Molecular Chaperones Human genes 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
101100061197 Mus musculus Cyp27b1 gene Proteins 0.000 description 1
101150081016 NEK6 gene Proteins 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
101001123128 Oryctolagus cuniculus Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
238000013494 PH determination Methods 0.000 description 1
229910018828 PO3H2 Inorganic materials 0.000 description 1
108010037490 Peptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 4 Proteins 0.000 description 1
102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010064851 Plant Proteins Proteins 0.000 description 1
241000223960 Plasmodium falciparum Species 0.000 description 1
102000015499 Presenilins Human genes 0.000 description 1
108010050254 Presenilins Proteins 0.000 description 1
101150000851 ROC7 gene Proteins 0.000 description 1
102000001424 Ryanodine receptors Human genes 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000005844 autocatalytic reaction Methods 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000002715 bioenergetic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
-1 dimethyl cycloheximide Chemical compound 0.000 description 1
230000000073 effect on psoriasis Effects 0.000 description 1
230000000531 effect on virus Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000013210 evaluation model Methods 0.000 description 1
229960005167 everolimus Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
230000006650 fundamental cellular process Effects 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000005415 magnetization Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229940125788 non-immunosuppressive cyclophilin inhibitor Drugs 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
210000004261 periodontium Anatomy 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000037039 plant physiology Effects 0.000 description 1
235000021118 plant-derived protein Nutrition 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000004879 pulmonary tissue Anatomy 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000001324 spliceosome Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
108010029517 tacrolimus binding protein 1B Proteins 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
235000020234 walnut Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA2708021A 2007-12-04 2008-12-04 Procede permettant de detecter des effecteurs de l'activite protease de cis/trans isomerases Abandoned CA2708021A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102007058181.7		2007-12-04
DE102007058181		2007-12-04
PCT/EP2008/010303 WO2009071301A2 (fr)	2007-12-04	2008-12-04	Procédé permettant de détecter des effecteurs de l'activité protéase de cis/trans isomérases

Publications (1)

Publication Number	Publication Date
CA2708021A1 true CA2708021A1 (fr)	2009-06-11

Family

ID=40626932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2708021A Abandoned CA2708021A1 (fr)	2007-12-04	2008-12-04	Procede permettant de detecter des effecteurs de l'activite protease de cis/trans isomerases

Country Status (2)

Country	Link
CA (1)	CA2708021A1 (fr)
WO (1)	WO2009071301A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030055072A1 (en) *	2000-12-22	2003-03-20	Lu Kun Ping	Methods of inhibiting Pin1-associated states using a fredericamycin a compound

2008
- 2008-12-04 WO PCT/EP2008/010303 patent/WO2009071301A2/fr not_active Ceased
- 2008-12-04 CA CA2708021A patent/CA2708021A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
WO2009071301A2 (fr)	2009-06-11
WO2009071301A3 (fr)	2009-08-13

Publication	Publication Date	Title
US7256013B2 (en)	2007-08-14	Kit for determining the acetylation level of a peptide based on sensitivity of the peptide to peptidase
Matic et al.	2008	In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy
JP4095805B2 (ja)	2008-06-04	ユビキチンリガーゼアッセイ
WO2008057434A2 (fr)	2008-05-15	Procédé d'identification de modulateurs de la voie nrf2-keap1-are
Stephens et al.	1997	Serine 331 and tyrosine 333 are both involved in the interaction between the cytosolic domain of TGN38 and the μ2 subunit of the AP2 clathrin adaptor complex
JP2002522747A (ja)	2002-07-23	微小管脱重合インヒビターを検出するためのアッセイ
JP2001514849A (ja)	2001-09-18	コイルドコイルおよび付加部位を含むポリペプチド
AU2011266816B2 (en)	2015-12-17	Fluorescent -labelled diubiquitin substrate for a deubiquitinase assay
Liu et al.	2022	Analysis of functional surfaces on the actin nucleation promoting factor Dip1 required for Arp2/3 complex activation and endocytic actin network assembly
CA2495391A1 (fr)	2004-02-26	Procede d'analyse de composes ou d'agents pouvant diminuer l'activite de prostaglandine e synthetase microsomale ou de prostaglandine d synthetase hematopoietique
CA2708021A1 (fr)	2009-06-11	Procede permettant de detecter des effecteurs de l'activite protease de cis/trans isomerases
US10234459B2 (en)	2019-03-19	Sensors and assays for ubiquitin or ubiquitin-like proteins
US20040082021A1 (en)	2004-04-29	Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin E synthase or hematopoietic prostaglandin D synthase
WO2009009773A1 (fr)	2009-01-15	Utilisation de l'enzyme otubain pour cliver la polyubiquitine liée à la lysine 48
Hales et al.	2025	A Proteolytic Switch: USP5 controls SDE2 function via UBL-directed cleavage
Araya	2021	Identifying Novel Apoptotic and Non-Apoptotic Substrates of Caspases
US20060099713A1 (en)	2006-05-11	Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
US10030260B2 (en)	2018-07-24	Inducible reconstitution and real-time quantitative kinetic system for the study of intramembrane enzymes
PL243470B1 (pl)	2023-08-28	Sposób identyfikacji niskocząsteczkowych związków indukujących powstawanie kompleksu trójskładnikowego oraz test płytkowy wykorzystujący taki sposób
WO2005021782A1 (fr)	2005-03-10	Procedes d'identification de modulateurs d'activite de proteasome
US20090298046A1 (en)	2009-12-03	Assays for Histone Deacetylase 1/2 Selective Inhibitors
EP1438584A4 (fr)	2006-12-27	Criblage iteratif assiste par cibles (tais), nouveau format de criblage pour grands repertoires moleculaires
KR20050042264A (ko)	2005-05-06	스테로이드생성 조절 및 조작을 위한 방법 및 조성물
Grou et al.	2012	Identification of a mammalian deubiquitinase that hydrolyzes the soluble Ub-PEX5 thioester conjugate

Legal Events

Date	Code	Title	Description
2011-12-05	FZDE	Discontinued